

Remarks

Applicant has canceled claims 1-142 and have added new claims 143-147. Support for the added claims is found in the specification and claims as filed.

Support relating to “method of inducing tumor cell death” is found, for example, on page 21 lines 16-23 and 31-32, page 22, lines 2-9, and page 23 lines 20-24 of the specification.

Support relating to “administering to a subject, a therapeutically effective amount of an MHC HLA-DR ligand” is found, for example, on page 9, lines 11-14 of the specification.

Support relating to “MHC HLA-DR ligand is anti-HLA-DR antibody” is found, for example, on page 25, lines 13-18 of the specification.

Support relating to “effective to induce tumor cell death in HLA-DR-expressing tumor cells” is found, for example, on page 22 lines 2-9 of the specification.

Support relating to “cancer is selected from the group consisting of multiple myeloma, lymphoma’s including Hodgkin’s lymphomas, lymphocytic lymphomas and leukemias” is found, for example, on page 23, lines 20-32 of the specification.

Support relating to “administered intravenously” is found, for example, on page 69, lines 5-7 and 14-15 of the specification.

Support relating to “administered parenterally” is found, for example, on page 68 line 27 – page 69 line 18 of the specification.

Pursuant to 37 C.F.R. § 1.604(a), Applicant seeks to have an interference declared with US 6,416,958 B1 (Vidovic), issued July 9, 2002. Applicant seeks to have an interference declared with US 6,416,958 B1 because the subject matter claimed in US 6,416,958 B1 was invented by Applicant as is disclosed in one or more of the applications to which this application claims priority, such as the application now pending as US Patent Application Serial Number 09/277,575.

Both claim 1 of this application (deriving support from US Patent Application Serial Number 09/277,575) and US 6,416,958 B1 claim a method of killing tumor cells by administering to a subject an anti-HLA-DR antibody to kill the tumor cell.

Applicant proposes a count for an interference as follows:

Proposed Count 1


Claim 1 of US 6,416,958 B1

or

Claim 1 of this application

Claim 143 presented above corresponds to the proposed count. Claim 1 of US
6,416,958 B1 corresponds to the proposed count.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read 'Helen Lockhart', written over a horizontal line.

Helen Lockhart, Reg. No. 39,248
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Attorney Docket No. V00139.70071.US
Date: July 9, 2003